S
Santhera Pharmaceuticals
Santhera Pharmaceuticals is a Swiss specialty company dedicated to developing innovative medicines for rare neuromuscular diseases with significant unmet medical needs
About Santhera Pharmaceuticals
Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on the development and commercialization of therapies for rare neuromuscular and pulmonary diseases with high unmet medical needs. Founded in 2004 through the merger of two companies, MyoContract AG and Graffinity Pharmaceuticals AG, by Klaus Schollmeier, Thomas Meier, Stephan Witthauer, and Thomas von Romano, Santhera is headquartered in Pratteln, Switzerland.
The company's lead product is AGAMREE® (vamorolone), a dissociative steroid that has been approved in the European Union and the United Kingdom for the treatment of Duchenne muscular dystrophy (DMD). AGAMREE® works by binding to the same receptors as corticosteroids but modifies their downstream activity, demonstrating a similar efficacy profile to traditional corticosteroids with a favorable safety and tolerability profile. The U.S. Food and Drug Administration (FDA) also granted full approval for AGAMREE® for the treatment of DMD in patients aged two years and older. Santhera has out-licensed the rights for this drug in North America to Catalyst Pharmaceuticals and in China to Sperogenix Therapeutics.
Santhera's business model revolves around acquiring, developing, and commercializing treatments for orphan diseases. The company generates revenue through product sales and licensing agreements. It serves patients suffering from rare diseases where few or no treatment options exist, operating in the orphan drug market. The company has faced financial challenges, including a restructuring in 2019 after a clinical trial failure, but has since regained footing with the approval and launch of AGAMREE®.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2006
- Outcome tier
- Colt$25–100M revenue
News
Open roles
Santhera Pharmaceuticals in the Pratteln ecosystem
The Santhera Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
NGN Capital
Novartis Venture Fund
Series B and later2 investors entered at this stage
- HMHighbridge Capital Management
CBC Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Santhera Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Santhera Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

